Serum amyloid A (SAA) as a predictor of chronic obstructive pulmonary disease (COPD) exacerbations.

Abstract

SAA is a novel inflammatory biomarker. There are still few studies&nbsp;devoted to the role of SAA in COPD exacerbation. <b>Aim:</b> to determine the role of SAA level, as a predictor of COPD exacerbations. <b>Materials and Methods:</b> we evaluated 48 mild to severe COPD patients according to GOLD (age – 62,12±1.15 yrs, male – 41 (85,4%)), FEV1 was 48,3 [40,4–61,9]% pred. We examined pts twice on Visit 1 and Visit 2 (3 month after visit 1). Measurements included clinical status, spirometry, serum levels of SAA. <b>Results:</b> during the observation period, in 11 COPD pts exacerbation was developed. SAA level of exacerbated pts was significantly elevated compared to the level in stable COPD pts (p=0,000) (figure 1). According to ROC analysis cut off value for SAA level&nbsp;in COPD exacerbated pts was 403,8 ng/ml (figure 2). High SAA level was associated with COPD exacerbation (OR=5,1 (95% CI:1,4–35,2) p=0,016). <b>Conclusions:</b> SAA level higher than 403,8 ng/ml can be a predictor of COPD exacerbation. High SAA level (≥403,8 ng/ml) increases risk of COPD exacerbation in 5,1 times.